NeoImmuneTech(NIT) is led by a highly experienced team of scientists, clinicians and financial experts, relentlessly pursuing the development of novel cancer and immune therapies.

Se Hwan Yang, Ph.D. - Co-president / Chief Executive Officer
Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and Hyleukin-7TM drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experiences of research, product development and business in life sciences, including molecular biology, immunology and protein engineering.
Richard Kang, Ph.D. - Co-president / Chief Executive Officer
Dr. Richard Kang has served as Chief Operating Officer and Chief Financial Officer since 2015 and 2018, respectively. Dr. Kang joined NeoImmuneTech’s Board of Directors in January 2014. Dr. Kang is an active serial entrepreneur. He has served as Board of Directors and Chief Operating Officer at NeuroBo Pharmaceuticals, Inc. and has served as Board of Directors and Chief Executive Officer at JK BioPharma Solutions, Inc. Prior to diving in Bio/Pharmaceutical industry, he had been achieved scientific publications including Cell and Nature as a scientist in Genetics, Molecular and Cellular Biology and Pathology. Dr. Kang holds B.S. and M.S. from Seoul National University in Korea and Ph.D. from the University of Edinburgh in UK and was a postdoctoral visiting fellow at National Cancer Institute, NIH.
NgocDiep (“Diep”) Le, M.D., Ph.D. - Executive Vice President / Chief Medical Officer
Dr. Le joined NeoImmuneTech in October 2018 as the Chief Medical Officer (CMO). She is a trained medical oncologist with over 15 years of drug development experience across all phases of Oncology R&D, in both solid tumors and hematologic malignancies. Most recently, Dr. Le served as the CMO at Verastem where she led the company’s first NDA submission and successful approval of COPIKTRATM in multiple indications. Prior to Verastem, she was the Vice President in Immuno-Oncology Innovative Medicines at MedImmune, served as Global Clinical Program Head at Novartis Oncology, and Executive Medical Director at GSK where she successfully led the clinical development program for the MEK inhibitor trametinib (MEKINISTTM ) from the first-in-human study through FDA approval. Dr. Le began her industry career at Amgen as Medical Sciences Medical Director in Early Development Oncology. She received her B.S. in Biology from the California Institute of Technology, earned her MD and PhD in Cancer Biology from Stanford University School of Medicine. Dr. Le completed a Medical Oncology Fellowship at the Duke University Comprehensive Cancer Center and was a faculty member at Duke University prior to joining biopharmaceutical industry.
Samuel Suhua Zhang, Ph.D, MBA - Chief Business Officer
Dr. Samuel Zhang joined NeoImmuneTech in May 2019 as Chief Business Officer. Dr. Zhang brings to NeoImmuneTech 18 years of industry experience covering the entire drug development spectrum, and the expertise to integrate market insight with scientific evaluation and clinical development feasibility for product positioning and value creation. Immediately prior to NeoImmuneTech, Dr. Zhang was vice president of strategy and business development at Merus, a world leading bispecific antibody company. Immediate before that, he was executive director and global head of Immuno-Oncology Strategy at Novartis. Dr. Zhang also held various management positions at Pfizer, Bristol-Myers Squibb (BMS), and Eli Lilly, responsible for product and portfolio strategies, business development, global and US launches, and medical affairs. While at BMS, Dr. Zhang designed the initial registration strategy for nivolumab that led to approval in 2L NSCLC and 2L RCC. Dr. Zhang also contributed to numerous business development projects, large and small, in various capacities (portfolio and product strategy, valuation/negotiation, medical and scientific evaluation, etc.) while at Pfizer, BMS, Novartis, and Merus. Dr. Zhang holds a Ph.D. in molecular biology from Columbia University, an M.B.A. from the Wharton School, and a B.S. in biology from Peking University.
Tae Woo Kim, CPA - Chief Financial Officer
Mr. Kim joined NeoImmuneTech, Inc. in May 2018 as Finance Director. His professional career began at PricewaterhouseCoopers (PwC) Korea in 2006. For 10+ years at PwC, he was mainly involved with financial audit services for Korean listed companies as a part of the Capital Market Group. Also, during his period at PwC, he successfully completed his secondment to another PwC territory, PwC Taiwan, for three years. This greatly increased his knowledge of Korean Capital Markets and overall global acumen. After that, he joined Englewood Lab, a New Jersey based company, and third US company listed on KOSDAQ, where he was CFO, responsible for all KOSDAQ listing-related matters. Mr. Kim holds his BA in Business Administration from Korea University and acquired his CPA license from Korea Institute of Certified Public Accountant.